A Study of BLB-201 RSV Vaccine in Infants and Children
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05655182 |
|
Recruitment Status :
Recruiting
First Posted : December 19, 2022
Last Update Posted : March 12, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Respiratory Syncytial Virus Infections | Biological: PIV5-vectored RSV Vaccine (BLB-201) Low Dose Biological: PIV5-vectored RSV Vaccine (BLB-201) High Dose Drug: Placebo | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 137 participants |
| Allocation: | Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine (BLB-201) in RSV Seronegative and Seropositive Infants and Children |
| Actual Study Start Date : | March 9, 2023 |
| Estimated Primary Completion Date : | September 14, 2024 |
| Estimated Study Completion Date : | December 23, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Group 1, infants (age 18-59 months), RSV+, BLB201 10^6 PFU
6 RSV seropositive participants will be administered 10^6 PFU BLB-201 by intranasal route on Day 1
|
Biological: PIV5-vectored RSV Vaccine (BLB-201) Low Dose
BLB201 10^6 PFU |
|
Placebo Comparator: Group 1, infants (age 18-59 months), RSV+, Placebo
4 RSV seropositive participants will be administered placebo by intranasal route on Day 1
|
Drug: Placebo
The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10^6 PFU). |
|
Experimental: Group 2, infants (age 18-59 months), RSV+, BLB201 10^7 PFU
6 RSV seropositive participants will be administered 10^7 PFU BLB-201 by intranasal route on Day 1
|
Biological: PIV5-vectored RSV Vaccine (BLB-201) High Dose
BLB201 10^7 PFU |
|
Placebo Comparator: Group 2, infants (age 18-59 months), RSV+, Placebo
4 RSV seropositive participants will be administered placebo by intranasal route on Day 1
|
Drug: Placebo
The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10^6 PFU). |
|
Experimental: Group 3, children (age 8-24 months), RSV+ or RSV-, BLB201 10^6 PFU
16 participants will be administered BLB201 10^6 PFU by intranasal route on Day 1
|
Biological: PIV5-vectored RSV Vaccine (BLB-201) Low Dose
BLB201 10^6 PFU |
|
Placebo Comparator: Group 3, children (age 8-24 months), RSV+ or RSV-, Placebo
8 participants will be administered placebo by intranasal route on Day 1
|
Drug: Placebo
The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10^6 PFU). |
|
Experimental: Group 4, children (age 6-24 months), RSV+ or RSV-, BLB201 10^7 PFU
32 participants will be administered BLB201 10^7 PFU by intranasal route on Day 1
|
Biological: PIV5-vectored RSV Vaccine (BLB-201) High Dose
BLB201 10^7 PFU |
|
Active Comparator: Group 4, children (age 8-24 months), RSV+ or RSV-, Placebo
16 participants will be administered placebo by intranasal route on Day 1
|
Drug: Placebo
The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10^6 PFU). |
|
Experimental: Group 6, children (age 8-24 months), RSV+ or RSV-, BLB201 10^7 PFU
30 participants will be administered BLB201 10^7 PFU by intranasal route on Day 1 and Day 57
|
Biological: PIV5-vectored RSV Vaccine (BLB-201) High Dose
BLB201 10^7 PFU |
|
Placebo Comparator: Group 6, children (age 8-24 months), RSV+ or RSV-, Placebo
15 participants will be administered Placebo by intranasal route on Day 1 and Day 57
|
Drug: Placebo
The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10^6 PFU). |
- Solicited Adverse Events [ Time Frame: Day 1-15 ]Frequencies and grades of solicited local and systemic AEs during a 14-day period after dosing.
- Unsolicited Adverse Events [ Time Frame: Day 1-29 ]Frequencies and grades of unsolicited AEs during a 28-day period after dosing.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 8 Months to 5 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria for sero+ children 18 to 59 months of age enrolled in Groups 1 and 2:
Healthy children at least 18 months but less than 60 months of age whose legally-acceptable representative (LAR) understands and signs the trial informed consent and agrees to vaccine administration following a detailed explanation of the trial.
Determined by medical history, targeted physical exam, and clinical judgement of the investigator to be in a good state of health. Screening laboratory values slightly outside lab normal ranges may be acceptable if the site investigator determines that they are not clinically significant. Permitted concomitant medications include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including topical steroids, topical antibiotics, and topical antifungal agents.
Sero+ for RSV as defined by serum RSV antibody titer assay
Participant is expected to be available for the duration of the trial.
The LAR confirms that the subject has received routine immunizations appropriate for age based on the current Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger.
Growing normally for age as demonstrated on a World Health Organization (WHO) growth chart, AND has a current height and weight above the 3rd percentile for age.
Inclusion criteria for sero+ or sero- infants and children 8 to 24 months of age enrolled in Groups 3 through 6:
Healthy children at least 8 months but less than 25 months of age whose LAR understands and signs the trial informed consent and agrees to vaccine administration following a detailed explanation of the trial.
Determined by medical history, targeted physical exam, and clinical judgement of the investigator to be in a good state of health. Screening laboratory values slightly outside lab normal ranges may be acceptable if the site investigator determines that they are not clinically significant. Permitted concomitant medications include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including topical steroids, topical antibiotics, and topical antifungal agents.
Sero- OR sero+ for RSV antibody, defined by serum RSV antibody titer assay not more than 30 days prior to vaccination.
Participant is expected to be available for the duration of the trial.
The LAR confirms that subject has received routine immunizations appropriate for age based on the current Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger.
Growing normally for age as demonstrated on a World Health Organization (WHO) growth chart, AND
If <1 year of age: has a current height and weight above the 5th percentile for age.
If ≥1 year of age: has a current height and weight above the 3rd percentile for age.
Subject Exclusion Criteria
<8 months of age and >60 months of age at the time of planned vaccine inoculation.
Born at less than 34 weeks gestation for subjects ≥ 1 year of age at enrollment
Born at less than 37 weeks gestation, and at the date of inoculation less than 1 year of age.
Maternal history of a positive HIV test before or during pregnancy.
Maternal history of illicit drug abuse or alcohol abuse.
Evidence of chronic disease except for chronic diseases that are mild, stable and not immune compromising or require recent change (< 60 days) in management (e.g., mild stable eczema, mild allergic rhinitis)
Clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality as determined by medical history or physical exam.
Acute or chronic medical condition or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgement, make the participant inappropriate for the study.
History of severe infection (e.g., requiring hospitalization).
Known or suspected impairment of immunological functions, bone marrow/solid organ transplant recipients.
Receiving immunosuppressive therapy including systemic corticosteroids.
Major congenital malformations, including congenital cleft palate or cytogenetic abnormalities.
Suspected or documented developmental disorder, delay, or other developmental problem.
Cardiac abnormality requiring treatment. Participants with clinically insignificant cardiac abnormalities (e.g., clinically insignificant patent foramen ovale) requiring no treatment may be enrolled.
Lung disease or reactive airway disease.
History of wheezing episode/s or receipt of bronchodilator therapy
Previous receipt of supplemental oxygen therapy in a home setting.
History of severe RSV infection or severe respiratory virus infection (e.g., requiring hospitalization).
Previous immunization with an investigational RSV vaccine.
Previous or planned administration of any anti-RSV antibody product within 6 months of receipt of study vaccine.
Previous receipt of immunoglobulin or any other antibody products within the past 6 months.
Previous receipt of any blood products within the past 6 months.
Previous anaphylactic reaction.
Previous serious vaccine-associated adverse reaction or one that was Grade 3 or above.
Known hypersensitivity to any study vaccine product component.
Household contact with any of the following groups of individuals for the period up to 28 days after vaccination (including after each dose for cohorts receiving two doses of vaccine):
Member of a household that contains an infant who is less than 6 months of age at the date of inoculation through the 28th day after inoculation. In groups assigned to two doses of vaccine, to include date of inoculation through the 28th day after the second inoculation.
Pregnant woman.
Persons with hospitalization for asthma or other chronic respiratory disease in the past 5 years.
Member of a household that, at the date of inoculation through the 28th day after inoculation (including second dose if scheduled), contains an immunocompromised individual including but not limited to:
A person who is HIV-infected.
A person who has cancer and has received chemotherapy within the 12 months prior to enrollment.
A person with a solid organ or bone marrow transplant.
A person currently receiving immunosuppressive agents.
Attends a daycare facility that does not separate children by age and contains an infant
<6 months of age at the date of inoculation through the 28th day after inoculation.
Neurological and neurodevelopmental conditions (e.g., cerebral palsy, epilepsy, stroke, seizures).
History of postinfectious or postvaccine neurological sequelae.
Autoimmune, inflammatory, vascular, or rheumatic disease.
Household contact of another child enrolled into the trial.
Inadequate venous access for repeated phlebotomy.
Subject's LAR/s who, in the opinion of the site investigator, are not suitable participants for the study, for any reason not previously delineated, including subjects with any condition that would in the opinion of the site investigator place the subject at unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
Subjects testing positive for infection with RSV, Influenza, or SARS-CoV-2 in the 3 months prior to enrollment.
Planned receipt of any of the following prior to planned trial vaccine receipt (Day 1 and Day 57 for group receiving 2 doses of vaccine):
Inactivated influenza vaccine within 14 days prior, or
Any other inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days prior, or
Any live vaccine, other than rotavirus vaccine, within the 28 days prior, or
Another investigational vaccine or investigational drug within 28 days prior.
Salicylate (aspirin) or salicylate-containing products within 28 days prior.
Planned receipt of any of the following after planned trial vaccine receipt (Day 1 and Day 57 for groups receiving 2 doses of vaccine):
Inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days after, or
Any live vaccine other than rotavirus in the 28 days after, or
Another investigational vaccine or investigational drug in the 56 days after.
Planned receipt of any of the following medications within 7 days of trial enrollment and 7 days after trial vaccine (Day 1 and also Day 57 for groups receiving 2 doses of vaccine):
Systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis, or systemic or nasal steroid therapy for acute illness.
Any other intranasal medications, or
Other prescription medications except permitted concomitant medications. Permitted concomitant medications (prescription or non-prescription) include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including (but not limited to) cutaneous (topical) steroids, topical antibiotics, and topical antifungal agents.
History of bleeding disorder or significant problem with bleeding
American Indian or Alaska Native Infants/Children (high risk for severe RSV infection) AND eligible to receive nirsevimab
Temporary exclusion criteria for sero+ children, sero- children, and infants:
The following are temporary or self-limiting conditions, and once resolved, the subject may be enrolled, if otherwise eligible. If the period of temporary exclusion is greater than 30 days, sero- children will need to be rescreened for levels of RSV neutralizing antibody.
Any of the following events at the time of enrollment:
Fever (temperature of ≥100.4°F per site standard based on age; e.g., oral for older children, rectal for infants, axillary screening), or
Upper respiratory signs or symptoms (rhinorrhea, cough, or pharyngitis) or
Nasal congestion significant enough to interfere with successful vaccination.
Otitis media.
Contact with a person diagnosed with RSV, Influenza, coronavirus disease-2 (COVID- 19) or other viral respiratory illnesses within the preceding 10 days.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05655182
| Contact: Marinka Tellier | 7062017798 | mtellier@cyanvacllc.com | |
| Contact: Henry Radziewicz, MD PhD | HRadziewicz@bluelakebiotechnology.com |
| United States, California | |
| Paradigm Clinical Research | Recruiting |
| La Mesa, California, United States, 91942 | |
| Contact: Cheryl Bolovits 858-274-4226 cbolovits@Paradigm-research.com | |
| Principal Investigator: Shaun Berger, MD | |
| Peninsula Research Associates | Recruiting |
| Rolling Hills Estates, California, United States, 90274 | |
| Contact: Heather Mendoza 310-265-1623 ext 302 heathermendoza@peninsularesearch.com | |
| Principal Investigator: Lawrence Sher, MD | |
| United States, Idaho | |
| Velocity Clinical Research, Boise | Recruiting |
| Meridian, Idaho, United States, 83642 | |
| Contact: Nicholas Tuttle 208-377-8653 ntuttle@velocityclinical.com | |
| Principal Investigator: Mark Turner, MD | |
| United States, Kansas | |
| AMR Newton | Recruiting |
| Newton, Kansas, United States, 67114 | |
| Contact: Anna M Hogan, BS 316-282-0828 anna.hogan@amrllc.com | |
| Principal Investigator: Troy Holdeman, MD | |
| United States, Michigan | |
| Great Lakes Research Institute | Recruiting |
| Southfield, Michigan, United States, 48075 | |
| Contact: Theodore R. Falcon 248-864-5242 tfalcon@greatlakesresearch.org | |
| Principal Investigator: Derrick A. Williamson, DO | |
| United States, Nebraska | |
| Velocity Clinical Research, Hastings | Recruiting |
| Hastings, Nebraska, United States, 68901 | |
| Contact: Erin Gorsuch 402-407-2800 egorsuch@velocityclinical.com | |
| Principal Investigator: Daniel Leonard, DO | |
| United States, Ohio | |
| Velocity Clinical Research, Cleveland | Recruiting |
| Beachwood, Ohio, United States, 44122 | |
| Contact: Melinda Delong 216-682-0320 mdelong@velocityclinical.com | |
| Principal Investigator: Margaret Rhee, MD | |
| Cincinnati Children's Hospital Medical Center | Recruiting |
| Cincinnati, Ohio, United States, 45229 | |
| Contact: Jamie Kidd, MSN, APRN 513-636-8981 Jamie.kidd@CCHMC.org | |
| Principal Investigator: Paul Spearman, MD | |
| United States, Texas | |
| Velocity Clinical Research, Austin | Recruiting |
| Cedar Park, Texas, United States, 78613 | |
| Contact: Angel Cervantes 512-506-8287 acervantes@velocityclinical.com | |
| Principal Investigator: Michael Zimmerman, MD | |
| Baylor College of Medicine | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Nanette Bond, PA-C 713-798-7467 nbond@bcm.edu | |
| Principal Investigator: Erin Nicholson, MD, MS | |
| Principal Investigator: | Paul Spearman, MD | Children's Hospital Medical Center, Cincinnati |
| Responsible Party: | Blue Lake Biotechnology Inc. |
| ClinicalTrials.gov Identifier: | NCT05655182 |
| Other Study ID Numbers: |
BLB-201-002 |
| First Posted: | December 19, 2022 Key Record Dates |
| Last Update Posted: | March 12, 2024 |
| Last Verified: | March 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | De-identified IPD underlying the results reported in any published articles (text, tables, figures, appendices) will be shared. |
| Supporting Materials: |
Study Protocol |
| Time Frame: | 5 years, beginning as soon as possible (but no later than 12 months) after article publication. |
| Access Criteria: | Data will be made available to investigators and institutions upon request. Requests should be directed to the Blue Lake Biotechnology Inc authors of the publication(s). |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Human respiratory syncytial virus (RSV) Lower respiratory tract infection (LRTI) |
|
Respiratory Syncytial Virus Infections Infections Virus Diseases Pneumovirus Infections Paramyxoviridae Infections |
Mononegavirales Infections RNA Virus Infections Vaccines Immunologic Factors Physiological Effects of Drugs |